Research programme: heart failure therapeutics - Orion
Latest Information Update: 22 Sep 2009
At a glance
- Originator Orion
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 22 Sep 2009 Discontinued - Preclinical for Heart failure in Finland (unspecified route)
- 08 Nov 2006 Preclinical trials in Heart failure in Finland (unspecified route)